Orchestra BioMed Holdings OBIO
Orchestra BioMed Holdings FY 2023: revenue $2.8M, down 22%; diluted EPS −$1.48
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-24-004083
- Document
- 10-K
- Exhibit 4.16
- Warrants or notes
- Exhibit 10.33
- Material contract
Key figures from this report
These are the numbers Orchestra BioMed Holdings reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$2.8M−22% from $3.5M in FY 202210-K income statement, on EDGAR
- Net income−$49.1MAgainst −$2.7M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$1.48Against −$0.17 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$30.6M+17346% from $175K in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$46.1MAgainst −$1.6M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- Myomo MYO public float $62M, Jun 30, 2025
- Edap TMS EDAP public float $62M, Jun 30, 2025
- InspireMD NSPR public float $61M, Jun 30, 2025
- Cytosorbents CTSO public float $61M, Jun 30, 2025
- Pro Dex PDEX public float $68M, Dec 31, 2025